TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis

Documenti analoghi

• TAS-102 plus bevacizumab versus TAS-102 alone for metastatic colorectal cancer: a systematic review and meta-analysis
  di: Jing Yuan, et al.
  Pubblicazione: (2025-11-01)
• TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis
  di: Ritam Joarder, et al.
  Pubblicazione: (2025-04-01)
• TAS-102 in combination with bevacizumab for second-line treatment of metastatic colorectal cancer with a hypertensive elderly patient: a case report
  di: Lingling Xu, et al.
  Pubblicazione: (2025-03-01)
• Сonfirmatory study of the efficacy and tolerability of trifluridine/tipiracil (TAS-102) therapy in the Russian population with chemorefractory metastatic colorectal cancer
  di: M. Yu. Fedyanin, et al.
  Pubblicazione: (2020-12-01)
• Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment
  di: Alessandro Ottaiano, et al.
  Pubblicazione: (2024-04-01)